IceCure Medical achieved a significant milestone with FDA marketing authorization for its ProSense system to treat low-risk breast cancer, positioning the company for enhanced growth and increased market penetration.

• FDA authorization targets a market of approximately 200,000 patients annually, predominantly women over 70 or those ineligible for surgery.
• ProSense is expected to be the only cryoablation system cleared in the U.S. for breast cancer, imposing high barriers for potential competitors.
• Increasing interest from U.S. clinicians and commercial sites, with plans for a post-market study to expand utilization and adoption.
• Anticipated CPT code increase in January 2026 to over $4,000 will enhance reimbursement prospects, supporting broader patient access.
• Global interest is rising post-authorization, with expansions in markets where ProSense is already approved, including recent gains in Switzerland.